Literature DB >> 2473761

Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies.

B M Bröker1, A Klajman, P Youinou, J Jouquan, C P Worman, J Murphy, L Mackenzie, R Quartey-Papafio, M Blaschek, P Collins.   

Abstract

A subset of B cells expressing the CD5 marker, a 67 KD molecule, has been implicated in the pathogenesis of autoimmune disease. To study the immunoglobulin repertoire of CD5+ B cells we investigated chronic lymphocytic leukemic (CLL) cells, since the majority of the malignant clones express CD5. CLL were induced to secrete their IgM in vitro by phorbol 12-myristate 13-acetate (PMA) and the supernatants screened for binding to a panel of autoantigens. Twelve out of 14 CLL clones were autoreactive, binding to Fc of IgG, ssDNA, dsDNA, histones, cardiolipin, or cytoskeletal components. Many also bound to more than one antigen tested for, showing multispecificity. Our data suggest that a high proportion of CD5+ B cells are programmed to secrete multispecific autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2473761     DOI: 10.1016/0896-8411(88)90068-6

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  40 in total

1.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

Review 2.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

3.  Analysis of expressed and non-expressed IGK locus rearrangements in chronic lymphocytic leukemia.

Authors:  Chrysoula Belessi; Kostas Stamatopoulos; Anastasia Hadzidimitriou; Katerina Hatzi; Tatjana Smilevska; Niki Stavroyianni; Fotini Marantidou; George Paterakis; Athanasios Fassas; Achilles Anagnostopoulos; Nikolaos Laoutaris
Journal:  Mol Med       Date:  2005 Jan-Dec       Impact factor: 6.354

4.  Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.

Authors:  Rosa Catera; Gregg J Silverman; Katerina Hatzi; Till Seiler; Sebastien Didier; Lu Zhang; Maxime Hervé; Eric Meffre; David G Oscier; Helen Vlassara; R Hal Scofield; Yifang Chen; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2008-09-25       Impact factor: 6.354

Review 5.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 6.  Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2015-02-03       Impact factor: 2.490

7.  Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.

Authors:  F Fais; B Sellars; F Ghiotto; X J Yan; M Dono; S L Allen; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; M Schuster; V P Vinciguerra; K Rai; F K Stevenson; P K Gregersen; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease.

Authors:  H E Baxendale; M Johnson; R C M Stephens; J Yuste; N Klein; J S Brown; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

10.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.